PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
September 16, 2025

Supplementary Figure S7 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

View Full Paper
Ask AI
Bookmark
Share

Authors

CSChantal F. StockemAGAlberto Gil-JimenezHAHamza Ali

Discussion

Loading...

Member takes

Overview

Analysis highlights tumor mutational burden distinctions in urothelial cancer responders and non-responders, indicating treatment dynamics.

Key Points

  • Tumor mutational burden (TMB) distinguishes responders from non-responders to ipilimumab and nivolumab.
  • In ipilimumab-high cohorts, TMB was observed to vary significantly between responders and non-responders.
  • Observational analysis showed distinct TMB patterns for patients in both ipilimumab-high and ipilimumab-low cohorts.
  • These findings highlight the potential role of TMB in predicting treatment outcomes for urothelial cancer.

Cite This Study

Stockem et al. (2025) studied this question.

synapsesocial.com/papers/68d4538731b076d99fa58955https://doi.org/10.1158/1078-0432.30125707
View Full Paper
Ask AI
Bookmark
Share